Monday's top analyst upgrades and downgrades included Amazon.com, Beyond Meat, Diamondback Energy, Enphase Energy, Groupon, Nuance Communications, PG&E, Spotify and ZoomInfo,
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
24/7 Wall St. found five stocks among Jefferies top U.S. growth calls for this week that look extremely attractive now. They are surviving nicely, with solid results posted and reasonably positive outlooks…
The top analyst upgrades, downgrades and initiations for Friday included Adobe, Biogen, Bristol-Myers, Broadcom, Charles Schwab, Ciena, Etsy, Gilead, Oracle, Sarepta, Snap and Wayfair.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
Friday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Alphabet, Altria, Amazon.com, Boeing, Caterpillar, Chipotle Mexican Grill, E*Trade, Gap, Snap and Twitter.
The top analyst upgrades, downgrades and initiations seen on Wednesday included AIG, Aqua America, CenterPoint Energy, Ferrari, GameStop, Medtronic, Roku, Salesforce.com and Uber Technologies.
The top analyst upgrades, downgrades and initiations seen on Monday included Amazon.com, Dover, Facebook, Lam Research, Newmont Mining, Occidental Petroleum, Six Flags, Tesla and 3D Systems.
The top analyst upgrades, downgrades and initiations seen on Thursday included Arena Pharmaceuticals, Autodesk, Coca-Cola, General Electric, Marvell, Monster Beverages, Nabors and Procter & Gamble.
Wells Fargo, Weatherford International, Huntington Bancshares, and Neurocrine Biosciences all posted new 52-week lows Wednesday.
Neurocrine Bio shares dipped on Wednesday after the company announced that its midstage Tourette syndrome study did not live up to expectations.
Chris Lange A series of new Stifel research reports focus on three biotech companies that have upcoming clinical data that could prove to be huge.
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
The top analyst upgrades, downgrades and initiations seen on Monday include Amazon, Anthem, Constellation Brands, Hecla Mining, Nike, Overstock.com and UnitedHealth.
